Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17391526
Miller AL, Garza AS, Johnson BH, Thompson EB (2007) Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 7, 3 17391526
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone no change compared to control glucocorticoid-sensitive cells
dexamethasone increase glucocorticoid-resistant cells

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone no change compared to control glucocorticoid-sensitive cells
dexamethasone increase glucocorticoid-resistant cells

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone no change compared to control glucocorticoid-sensitive cells
dexamethasone increase glucocorticoid-resistant cells

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone no change compared to control glucocorticoid-sensitive cells
dexamethasone increase glucocorticoid-resistant cells

S211-p - GR (human)
Modsite: PGkEtNEsPWRSDLL SwissProt Entrez-Gene
Orthologous residues
GR (human): S211‑p, GR iso2 (human): S211‑p, GR iso10 (human): S211‑p, GR (mouse): S220‑p, GR (rat): S232‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone increase in glucocorticoid-sensitive cells
dexamethasone increase in glucocorticoid-resistant cells
SP600125, U0126 dexamethasone inhibit treatment-induced increase in glucocorticoid-resistant cells
rapamycin dexamethasone no effect upon treatment-induced increase in glucocorticoid-resistant cells
colforsin dexamethasone augment treatment-induced increase in glucocorticoid-resistant cells
SP600125, U0126 colforsin inhibit treatment-induced increase in glucocorticoid-resistant cells
colforsin increase in glucocorticoid-resistant cells
rapamycin no change compared to control in glucocorticoid-resistant cells

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase glucocorticoid-resistant cells
colforsin inhibit treatment-induced increase in glucocorticoid-resistant cells
SP600125, U0126 inhibit treatment-induced increase in glucocorticoid-resistant cells
rapamycin inhibit treatment-induced increase in glucocorticoid-resistant cells
dexamethasone no change compared to control

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase glucocorticoid-resistant cells
colforsin inhibit treatment-induced increase in glucocorticoid-resistant cells
SP600125, U0126 inhibit treatment-induced increase in glucocorticoid-resistant cells
rapamycin inhibit treatment-induced increase in glucocorticoid-resistant cells
dexamethasone no change compared to control

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone increase
decrease glucocorticoid-resistant cells

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia, lymphoma, anaplastic large cell lymphoma
Relevant cell lines - cell types - tissues:  CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  GC-sensitive CEM-C7-14 and CEM-C1-6; GC-resistant EM-C1-15
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone increase
decrease glucocorticoid-resistant cells